Juan‐Manuel Sancho

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 324 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +4

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Gonzalo Gutiérrez, Teresa M. Cardesa‐Salzmann, Fina Climent et al. · Blood · 2011 · 317 citations · Full text

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Alexandra Valera, Armando López‐Guillermo, Teresa M. Cardesa‐Salzmann et al. · Haematologica · 2013 · 225 citations · Full text

Immunology, Pathology, Myc Amplifications +16

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry

Sandra Quijano, Antonio López, Juan‐Manuel Sancho et al. · Journal of Clinical Oncology · 2009 · 214 citations · Full text

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

Kennosuke Karube, Anna Enjuanes, Iván Dlouhy et al. · Leukemia · 2017 · 178 citations · Full text